Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 36.0 Cr.
- Current Price ₹ 36.0
- High / Low ₹ 61.5 / 30.6
- Stock P/E
- Book Value ₹ 33.9
- Dividend Yield 0.00 %
- ROCE 4.50 %
- ROE 1.29 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.06 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -1.02%
- The company has delivered a poor sales growth of -2.09% over past five years.
- Company has a low return on equity of 3.23% over last 3 years.
- Company has high debtors of 178 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
28.07 | 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 45.28 | |
25.75 | 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 43.01 | |
Operating Profit | 2.32 | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 2.27 |
OPM % | 8.27% | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 5.01% |
0.00 | 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | |
Interest | 0.52 | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.57 |
Depreciation | 0.72 | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.45 |
Profit before tax | 1.08 | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | -0.74 |
Tax % | 3.70% | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | |
1.04 | 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | -0.53 | |
EPS in Rs | 1.44 | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | -0.53 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | -2% |
3 Years: | -6% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | 0% |
3 Years: | 2% |
TTM: | -134% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 6% |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 3% |
3 Years: | 3% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 |
Reserves | 6.99 | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 21.82 | 23.82 | 23.88 |
15.70 | 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.61 | |
11.20 | 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.87 | 7.55 | 14.43 | |
Total Liabilities | 41.13 | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 64.92 |
5.48 | 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 11.00 | |
CWIP | 13.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 1.78 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 |
21.81 | 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 50.52 | |
Total Assets | 41.13 | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 64.92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.18 | 2.28 | 1.75 | 3.05 | 1.70 | 6.88 | 1.19 | 2.48 | 1.62 | 0.77 | 2.24 | 1.96 | |
-9.65 | -2.14 | -1.10 | 0.23 | -1.04 | -2.21 | -0.34 | -0.84 | -3.67 | -2.44 | -2.27 | -1.21 | |
7.63 | -0.17 | -0.70 | -3.42 | -3.94 | -4.80 | -0.73 | -1.79 | 2.07 | 1.68 | 0.05 | -0.69 | |
Net Cash Flow | -0.84 | -0.03 | -0.06 | -0.14 | -3.28 | -0.13 | 0.12 | -0.15 | 0.02 | 0.01 | 0.03 | 0.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 205.06 | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 177.78 |
Inventory Days | 55.54 | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 |
Days Payable | 144.69 | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 38.90 |
Cash Conversion Cycle | 115.91 | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 341.59 |
Working Capital Days | 126.52 | 116.00 | 146.84 | 169.18 | 62.86 | 142.76 | 171.72 | 165.15 | 205.86 | 198.84 | 243.14 | 301.64 |
ROCE % | 6.31% | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 6.01% | 4.50% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copy of News Paper publication for quarter results ending September 30, 2024.
- Financial Results For Q2 Ending Sep 30, 2024 13 Nov
-
Board Meeting Outcome for Financial Results For Quarter Ended 30 September 2024
13 Nov - Approved un-audited financial results for Q2 2024.
-
Board Meeting Intimation for Quarterly Results For 30 September, 2024
6 Nov - Board meeting scheduled to approve Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Oct - Certificate under Regulation 74(5) of SEBI submitted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio:[1]
a) Pharmaceutical Ready to fill Pellets
b) Multiple Unit Pellet System (MUPS)
c) Tissue Bio Adhesive
d) Injectables (Small Volume Parenterals)
e) Oral Solid Dosages (Tablets & Capsules)
f) Liquid Orals (Syrups & Suspensions)
g) Dry Syrup (Powder)